Savvy Advisors Inc. Buys 6,646 Shares of AbbVie Inc. $ABBV

Savvy Advisors Inc. boosted its stake in AbbVie Inc. (NYSE:ABBV) by 22.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 36,568 shares of the company’s stock after buying an additional 6,646 shares during the period. Savvy Advisors Inc.’s holdings in AbbVie were worth $8,355,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Evolution Wealth Management Inc. bought a new stake in shares of AbbVie during the second quarter worth approximately $26,000. Chelsea Counsel Co. bought a new position in shares of AbbVie during the third quarter worth approximately $26,000. Westend Capital Management LLC acquired a new stake in AbbVie during the 4th quarter worth approximately $29,000. Texas Capital Bancshares Inc TX acquired a new stake in AbbVie during the 3rd quarter worth approximately $31,000. Finally, Caitlin John LLC bought a new stake in AbbVie in the 3rd quarter valued at $33,000. 70.23% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ABBV has been the topic of several recent research reports. BMO Capital Markets reiterated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Citigroup decreased their price target on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 27th. UBS Group lowered their price target on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. Finally, William Blair reiterated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and a consensus target price of $253.15.

Insider Activity at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.25% of the stock is currently owned by insiders.

AbbVie Price Performance

Shares of NYSE ABBV opened at $208.79 on Friday. The business has a fifty day moving average price of $221.58 and a two-hundred day moving average price of $224.47. The stock has a market capitalization of $369.17 billion, a PE ratio of 88.47, a P/E/G ratio of 0.73 and a beta of 0.38. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same period in the prior year, the firm posted $2.16 EPS. AbbVie’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.